Impact of familial risk factors on management and survival of women with early-onset breast cancer

 

 

One of the most important risk factors for breast cancer is the occurrence of breast or ovarian cancer among family members. Treatment guidelines of breast cancer occurring in patients with an increased familial risk are not well established and conflicting data exist on the impact of a family history of breast or ovarian cancer on the outcome of breast cancer. We used population-based data from the Geneva familial breast cancer registry study to compare tumour characteristics, treatment patterns and survival of early-onset (≤50 years) breast cancer patients with a strong family history with those of early-onset patients without affected first or second degree relatives. Compared to patients at low familial risk (n=575), those at high familial risk (n=58) were not more frequently detected by screening nor at an earlier stage. High familial risk patients received significantly more often systemic therapy, especially for node-negative or receptor-positive disease. Five year disease-specific survival rates of patients at high versus low familial risk were 86% and 90% respectively. After adjustment for other prognostic variables, there was no difference in breast cancer mortality in general. A strong family history was, however, associated with a non-significantly increased breast cancer mortality risk in patients ≤40 years (adjusted hazard ratio [HR] 4.0, 95% CI 0.8-19.7) and in patients treated without chemotherapy (adjusted HR 2.7, 95% CI 0.6-12.5).  

Based on this study, we conclude that guidelines on screening and management of young women at high familial risk are needed. Additional research is required to confirm whether a strong family history of breast cancer impairs survival of very young patients and those treated without chemotherapy.

 

Bibliographical reference:

Verkooijen HM et al.: "Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study", Br J Cancer. 2006 Jan 30;94(2):231-8

 

 

Helena M Verkooijen, Christine Bouchardy 

Geneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University, Switzerland